Roche, in the derby with Novartis, the Japanese variable appears

The report of the purchase of securities of the Swiss pharmaceutical giant Roche by the Japanese finance multinational SoftBank certainly did not go unnoticed. On the Swiss market, in particular, the move raises questions and causes discussion. The operation, indicated in recent days by the Bloomberg agency, has not found confirmation in the parties involved, but has been picked up by various media and on the Swiss market it is given by many as plausible and realistic. SoftBank would …